Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity
Thao N.D. Pham, … , David J. Bentrem, Hidayatullah G. Munshi
Thao N.D. Pham, … , David J. Bentrem, Hidayatullah G. Munshi
Published April 5, 2022
Citation Information: JCI Insight. 2022;7(9):e152731. https://doi.org/10.1172/jci.insight.152731.
View: Text | PDF
Research Article Immunology

Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity

  • Text
  • PDF
Abstract

To elicit effective antitumor responses, CD8+ T cells need to infiltrate tumors and sustain their effector function within the immunosuppressive tumor microenvironment (TME). Here, we evaluate the role of MNK activity in regulating CD8+ T cell infiltration and antitumor activity in pancreatic and thyroid tumors. We first show that human pancreatic and thyroid tumors with increased MNK activity are associated with decreased infiltration by CD8+ T cells. We then show that, while MNK inhibitors increase CD8+ T cells in these tumors, they induce a T cell exhaustion phenotype in the tumor microenvironment. Mechanistically, we show that the exhaustion phenotype is not caused by upregulation of programmed cell death ligand 1 (PD-L1) but is caused by tumor-associated macrophages (TAMs) becoming more immunosuppressive following MNK inhibitor treatment. Reversal of CD8+ T cell exhaustion by an anti–PD-1 antibody or TAM depletion synergizes with MNK inhibitors to control tumor growth and prolong animal survival. Importantly, we show in ex vivo human pancreatic tumor slice cultures that MNK inhibitors increase the expression of markers associated with immunosuppressive TAMs. Together, these findings demonstrate a role of MNKs modulating a protumoral phenotype in macrophages and identify combination regimens involving MNK inhibitors to enhance antitumor immune responses.

Authors

Thao N.D. Pham, Christina Spaulding, Mario A. Shields, Anastasia E. Metropulos, Dhavan N. Shah, Mahmoud G. Khalafalla, Daniel R. Principe, David J. Bentrem, Hidayatullah G. Munshi

×

Figure 2

MNK inhibitors increase CD8+ T cells in tumors but induce a T cell exhaustive phenotype.

Options: View larger image (or click on image) Download as PowerPoint
MNK inhibitors increase CD8+ T cells in tumors but induce a T cell exhau...
Mice with established syngeneic pancreatic (KPC-344) and thyroid (TBP-3868) tumors were randomized and treated with DMSO (vehicle control), the MNK inhibitor CGP57380 (25 mg/kg), or the MNK inhibitor eFT508 (1 mg/kg) daily. (A and C) The collected tumors were analyzed for p-eIF4E expression by immunofluorescence staining and CD8+ T cells by IHC staining. Scale bar: 100 μm. The absolute number of stained CD8+ T cells per 10× section was quantified by ImageJ and averaged from 5 individual sections. (B and D) The collected tumors were digested and analyzed by flow cytometry for the number of CD8+ T cells. (E and F) Tumor-infiltrating CD8+ T cells were analyzed by flow cytometry for the expression of CD69, granzyme B (GzmB), perforin-1 (Prf1), and PD-1. Data points in B, D, E, and F represent individual tumors. (G and H) Tumor size was monitored and measured using calipers. Tumor volumes (V) were calculated using the formula V = (W2 × L)/2, where W is tumor width and L is tumor length. Arrows indicate start of treatment. Data are shown as the mean ± SEM, and analysis was done using 1-way ANOVA followed by Dunnett’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts